Journal
CURRENT OPINION IN INFECTIOUS DISEASES
Volume 22, Issue 1, Pages 11-17Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e3283210020
Keywords
drug-resistant tuberculosis; extensively drug-resistant tuberculosis; multidrug-resistant tuberculosis; South Africa; tuberculosis/HIV coinfection
Categories
Funding
- Fogarty International Center, National Institutes of Health [R24TW007988]
- Fogarty International Clinical Research Scholars Support Center
- Burroughs Wellcome Fund
- American Society of Tropical Medicine and Hygiene
Ask authors/readers for more resources
Purpose of review Physicians, researchers and policy makers must understand the myriad consequences of multidrug and extensively drug-resistant tuberculosis (TB) within the HIV community in order to guide clinical care, research and resource allocation. Recent findings Extensively drug-resistant TB can no longer be considered as occurring in isolated outbreaks as it has been reported in 45 countries from all regions of the world. HIV has been associated as an independent risk factor for infection with drug-resistant TB. HIV patients appear more likely to suffer from primary, transmitted resistance as opposed to developing acquired resistance during the course of treatment for TB. New rapid diagnostics offer promise of providing clinically useful first-line drug susceptibility information but require validation in HIV patients and smear negative individuals. Demonstration projects of community-based treatment of drug-resistant TB and integration of TB and HIV care provide opportunities to decentralize management of drug-resistant TB. Summary Multidrug-resistant and extensively drug-resistant TB disproportionately affect HIV patients and result in increased morbidity and mortality. In this study, we address these challenging issues and offer some short-term and longer term strategies for their alleviation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available